See more : West Island Brands Inc. (WIBFF) Income Statement Analysis – Financial Results
Complete financial analysis of Simulations Plus, Inc. (SLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Simulations Plus, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- FibraHotel (FIHO12.MX) Income Statement Analysis – Financial Results
- Penns Woods Bancorp, Inc. (PWOD) Income Statement Analysis – Financial Results
- Argo Group Limited (ARGO.L) Income Statement Analysis – Financial Results
- Mitsubishi Electric Corporation (MEL.L) Income Statement Analysis – Financial Results
- TUGA Innovations, Inc. (TUGA.CN) Income Statement Analysis – Financial Results
Simulations Plus, Inc. (SLP)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.simulations-plus.com
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.01M | 59.58M | 53.91M | 46.47M | 41.59M | 33.97M | 29.67M | 24.14M | 19.97M | 18.31M | 11.46M | 10.07M | 9.45M | 11.72M | 10.71M | 9.14M | 8.97M | 8.86M | 5.86M | 4.75M | 5.21M | 5.48M | 4.44M | 3.91M | 3.63M | 3.47M | 2.65M | 2.49M | 2.60M |
| Cost of Revenue | 26.86M | 11.63M | 10.82M | 10.60M | 10.65M | 9.03M | 7.99M | 6.31M | 4.60M | 4.32M | 1.63M | 1.65M | 1.51M | 2.88M | 2.55M | 2.32M | 2.10M | 2.08M | 1.60M | 1.51M | 1.56M | 1.54M | 1.46M | 1.56M | 1.16M | 1.65M | 1.76M | 1.25M | 1.20M |
| Gross Profit | 43.15M | 47.95M | 43.08M | 35.87M | 30.94M | 24.94M | 21.67M | 17.83M | 15.37M | 14.00M | 9.83M | 8.42M | 7.94M | 8.84M | 8.17M | 6.82M | 6.87M | 6.78M | 4.25M | 3.24M | 3.65M | 3.95M | 2.99M | 2.35M | 2.47M | 1.82M | 889.25K | 1.24M | 1.40M |
| Gross Profit Ratio | 61.63% | 80.48% | 79.92% | 77.19% | 74.39% | 73.43% | 73.05% | 73.87% | 76.96% | 76.43% | 85.79% | 83.65% | 84.02% | 75.44% | 76.23% | 74.61% | 76.58% | 76.49% | 72.60% | 68.27% | 70.09% | 71.96% | 67.23% | 60.08% | 67.98% | 52.45% | 33.62% | 49.77% | 53.85% |
| Research & Development | 5.75M | 4.50M | 3.21M | 4.05M | 2.97M | 2.50M | 1.79M | 1.37M | 1.45M | 1.33M | 952.77K | 802.37K | 947.56K | 935.20K | 969.87K | 1.11M | 990.49K | 814.95K | 445.25K | 524.56K | 515.02K | 379.63K | 382.14K | 354.09K | 299.88K | 218.51K | 390.45K | 133.02K | 100.00K |
| General & Administrative | 22.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.56M | 6.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 131.78K | 38.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.27M | 34.72M | 24.97M | 20.57M | 16.36M | 11.80M | 9.58M | 8.20M | 6.69M | 6.81M | 4.44M | 3.55M | 3.38M | 4.31M | 4.33M | 3.90M | 3.70M | 3.46M | 2.97M | 2.42M | 2.51M | 2.30M | 2.11M | 2.20M | 2.14M | 2.31M | 2.68M | 2.28M | 1.20M |
| Other Expenses | 0.00 | 2.97M | 204.00K | 0.00 | 14.30B | 14.30B | 8.14B | 0.00 | 0.00 | 0.00 | 0.00 | 35.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261.15K | 0.00 | 0.00 | 0.00 | 100.00K |
| Operating Expenses | 37.02M | 39.22M | 28.17M | 24.61M | 19.33M | 14.30M | 11.37M | 9.57M | 8.14M | 8.14M | 5.39M | 4.35M | 4.33M | 5.24M | 5.30M | 5.01M | 4.69M | 4.27M | 3.42M | 2.95M | 3.02M | 2.68M | 2.49M | 2.55M | 2.70M | 2.53M | 3.07M | 2.41M | 1.40M |
| Cost & Expenses | 63.88M | 50.85M | 39.00M | 35.21M | 29.98M | 23.32M | 19.37M | 15.87M | 12.74M | 12.46M | 7.02M | 6.00M | 5.84M | 8.12M | 7.84M | 7.33M | 6.79M | 6.36M | 5.02M | 4.46M | 4.58M | 4.22M | 3.94M | 4.12M | 3.87M | 4.18M | 4.83M | 3.66M | 2.60M |
| Interest Income | 4.38M | 4.13M | 717.00K | 201.00K | 29.47K | 33.52K | 27.12K | 15.86K | 18.01K | 17.94K | 31.44K | 49.49K | 89.27K | 91.86K | 101.55K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 233.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 717.00K | 22.00K | 0.00 | 109.08K | 153.03K | 38.19K | 18.01K | 17.94K | 31.44K | 49.49K | 3.00 | 118.00 | 1.05K | 93.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.67M | 3.84M | 3.57M | 3.59M | 2.96M | 2.75M | 2.72M | 2.14M | 1.93M | 1.99M | 1.04M | 766.96K | 715.44K | 747.30K | 682.94K | 561.01K | 543.42K | 512.45K | 363.18K | 206.89K | 223.98K | 195.60K | 191.83K | 293.85K | 261.15K | 503.76K | 632.09K | 139.86K | -100.00K |
| EBITDA | 11.80M | 12.57M | 18.49M | 14.70M | 11.85M | 13.31M | 11.72M | 10.38M | 9.17M | 7.68M | 5.48M | 4.84M | 4.67M | 4.52M | 3.79M | 2.59M | 2.72M | 3.02M | 1.20M | 503.32K | 850.21K | 1.46M | 691.94K | 91.90K | 24.49K | -205.28K | -1.70M | -1.03M | 100.00K |
| EBITDA Ratio | 16.85% | 14.64% | 27.66% | 24.65% | 28.50% | 39.54% | 43.98% | 43.15% | 45.95% | 32.97% | 38.36% | 48.90% | 46.74% | 37.88% | 34.12% | 26.98% | 29.43% | 33.96% | 19.85% | 10.40% | 16.33% | 26.68% | 15.57% | 2.35% | 0.60% | -10.25% | -61.53% | -30.75% | 3.85% |
| Operating Income | 6.13M | 8.73M | 11.34M | 7.86M | 8.89M | 10.65M | 10.30M | 8.26M | 7.23M | 5.86M | 4.44M | 4.07M | 3.61M | 3.60M | 2.87M | 1.81M | 2.18M | 2.50M | 833.14K | 296.43K | 626.23K | 1.27M | 500.11K | -201.95K | -236.66K | -709.05K | -2.18M | -1.17M | 200.00K |
| Operating Income Ratio | 8.76% | 14.64% | 21.03% | 16.92% | 21.38% | 31.35% | 34.71% | 34.24% | 36.21% | 31.98% | 38.74% | 40.44% | 38.23% | 30.72% | 26.80% | 19.82% | 24.29% | 28.26% | 14.23% | 6.24% | 12.03% | 23.07% | 11.25% | -5.16% | -6.52% | -20.45% | -82.58% | -46.90% | 7.69% |
| Total Other Income/Expenses | 6.28M | 2.97M | 204.00K | -168.00K | 2.50M | -92.73K | -158.85K | -24.02K | 4.59K | -163.60K | 73.93K | 184.41K | 342.77K | 169.40K | 233.87K | 214.83K | 268.03K | 121.69K | 55.64K | 51.69K | 72.40K | -7.44K | -13.60K | -22.05K | -19.34K | 133.98K | 116.84K | -305.99K | 0.00 |
| Income Before Tax | 12.41M | 11.70M | 15.12M | 11.09M | 11.39M | 10.56M | 10.14M | 8.24M | 7.24M | 5.69M | 4.51M | 4.26M | 3.95M | 3.77M | 3.10M | 2.03M | 2.45M | 2.62M | 888.78K | 348.12K | 698.63K | 1.26M | 486.52K | -224.00K | -256.00K | -575.07K | -2.07M | -1.48M | 0.00 |
| Income Before Tax Ratio | 17.73% | 19.63% | 28.04% | 23.86% | 27.38% | 31.08% | 34.18% | 34.14% | 36.23% | 31.08% | 39.38% | 42.27% | 41.85% | 32.17% | 28.98% | 22.17% | 27.28% | 29.63% | 15.18% | 7.32% | 13.42% | 22.94% | 10.95% | -5.72% | -7.05% | -16.59% | -78.17% | -59.17% | 0.00% |
| Income Tax Expense | 2.46M | 1.73M | 2.63M | 1.30M | 2.05M | 1.97M | 1.20M | 2.45M | 2.29M | 1.85M | 1.49M | 1.37M | 1.14M | 1.06M | 948.43K | 614.58K | 720.61K | 1.16M | 212.90K | 85.80K | -137.86K | -1.25M | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | -38.80K | 0.00 |
| Net Income | 9.95M | 9.96M | 12.48M | 9.78M | 9.33M | 8.58M | 8.93M | 5.79M | 4.95M | 3.84M | 3.03M | 2.89M | 3.03M | 2.71M | 2.16M | 1.41M | 1.73M | 1.47M | 675.88K | 262.32K | 836.49K | 2.51M | 484.92K | -225.60K | -257.60K | -576.67K | -2.07M | -1.44M | 0.00 |
| Net Income Ratio | 14.22% | 16.72% | 23.16% | 21.05% | 22.44% | 25.27% | 30.12% | 23.98% | 24.79% | 20.98% | 26.40% | 28.66% | 32.05% | 23.16% | 20.13% | 15.44% | 19.24% | 16.55% | 11.54% | 5.52% | 16.07% | 45.69% | 10.91% | -5.76% | -7.10% | -16.63% | -78.23% | -57.62% | 0.00% |
| EPS | 0.50 | 0.50 | 0.62 | 0.49 | 0.52 | 0.49 | 0.52 | 0.34 | 0.29 | 0.23 | 0.19 | 0.18 | 0.19 | 0.17 | 0.14 | 0.09 | 0.11 | 0.10 | 0.05 | 0.02 | 0.06 | 0.18 | 0.04 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| EPS Diluted | 0.49 | 0.49 | 0.60 | 0.47 | 0.50 | 0.48 | 0.50 | 0.33 | 0.29 | 0.23 | 0.18 | 0.18 | 0.19 | 0.17 | 0.13 | 0.08 | 0.10 | 0.08 | 0.04 | 0.02 | 0.05 | 0.17 | 0.03 | -0.02 | -0.02 | -0.04 | -0.62 | -0.49 | 0.00 |
| Weighted Avg Shares Out | 19.99M | 20.08M | 20.20M | 20.05M | 17.82M | 17.49M | 17.33M | 17.24M | 17.03M | 16.86M | 16.17M | 16.00M | 15.76M | 15.54M | 15.83M | 16.13M | 16.13M | 15.28M | 14.72M | 14.44M | 13.98M | 13.64M | 13.63M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
| Weighted Avg Shares Out (Dil) | 20.30M | 20.47M | 20.75M | 20.74M | 18.54M | 18.06M | 17.86M | 17.52M | 17.21M | 17.03M | 16.41M | 16.32M | 16.15M | 16.08M | 16.51M | 17.19M | 18.14M | 17.96M | 16.29M | 15.92M | 15.58M | 14.96M | 14.10M | 13.58M | 13.54M | 13.51M | 3.33M | 2.94M | 2.22M |
Simulations Plus (SLP) to Report Q1 Earnings: What's in Store?
Simulations Plus (SLP) fiscal first-quarter performance is likely to have benefited from momentum across Software and Services business segments.
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Management will host a conference call that same day at...
Simulations Plus Outlines Paths to Win at 2023 Investor Day
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a virtual investor day today, Nov. 14, 2023, starting at 1:00 pm ET, with presentations by the Company's leadership team.
Simulations Plus to Host Investor Day on Tuesday, November 14th
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, and the leadership team will participate in the Company's virtual Investor Day on Tuesday, Nov 14, at 1 p.m. ET.
Simulations Plus, Inc. (SLP) Q4 2023 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q4 2023 Earnings Conference Call October 25, 2023 5:00 PM ET Company Participants Tamara Gonzales - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants...
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 4th quarter and full fiscal year 2023. Total FY23 revenue increased 11% to $59.6 million.
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 25, 2023, at 5pm ET to discuss 4th quarter & fiscal year 2023 financial results.
Simulations Plus Receives New FDA Grant Award
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was awarded a new funded grant from the U.S. FDA to validate best practices for PBBM/PBPK modeling workflows to simulate VBE studies.
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus hosted its first University+ PBPK Summer Camp, an intensive 8-week PBPK modeling course for more than 80 attendees from 26 countries.
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
LANCASTER, Calif.--(BUSINESS WIRE)--Dr. Viera Lukacova, Chief Science Officer of Simulations Plus, was selected to be a Fellow of the American Association of Pharmaceutical Scientists.
Source: https://incomestatements.info
Category: Stock Reports